The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.
Approval Alert | Revumenib in Relapsed/Refractory KMT2A-Translocated Acute Leukemia
Advertisement
Advertisement
Trending on CancerNetwork
1
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data
2
Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?
3
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
4
The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer
5
